4-[2-[4-(三氟甲基)苯基]乙烯基]苯酚 | 40474-07-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 中文名称: 4-[2-[4-(三氟甲基)苯基]乙烯基]苯酚
• 英文名称: 4-Trifluormethyl-4'-hydroxy-stilben
• 英文别名: 4-{2-[4-(Trifluoromethyl)phenyl]ethenyl}phenol；4-[2-[4-(trifluoromethyl)phenyl]ethenyl]phenol
• CAS: 40474-07-5
• 化学式: C₁₅H₁₁F₃O
• 分子量: 264.247
• InChiKey: MYLRTMLNZICOLO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-[2-[4-(三氟甲基)苯基]乙烯基]苯酚 在 镍 氢气 作用下， 以 乙醇 为溶剂， 生成 4-(4-(trifluoromethyl)phenethyl)phenol
  参考文献：
  名称：

  Kozachuk,D.N. et al., Journal of Organic Chemistry USSR (English Translation), 1971, vol. 7, p. 1976 - 1981

  摘要：

  DOI：
• 作为产物：
  描述：

  4-三氟甲基苯甲酸 、 对羟基苯甲醛 在 哌啶 作用下， 生成 4-[2-[4-(三氟甲基)苯基]乙烯基]苯酚
  参考文献：
  名称：

  Searching for New Tools to Counteract the Helicobacter pylori Resistance: The Positive Action of Resveratrol Derivatives

  摘要：

  幽门螺杆菌耐药现象强调了需要采用新策略来提高根除率，包括联合具有协同作用的抗生素和非抗生素化合物的替代治疗方法。本研究评估了白藜芦醇-RSV和新合成的具有更高生物利用度的RSV-酚衍生物，单独和与左氧氟沙星-LVX联合使用，对耐药的幽门螺杆菌临床菌株的抗菌效应（MIC/MBC）和抗毒力效应（生物膜减少和游走运动抑制）。使用Galleria mellonella模型在体内进行了确认实验。在研究的RSV衍生物中，RSV-3和RSV-4相对于RSV具有更高的抗菌活性（MIC分别为6.25至200 µg/mL和3.12至200 µg/mL）。RSV、RSV-3和RSV-4能够与LVX协同作用，恢复其在七种临床耐药菌株中的效果。RSV、RSV-3和RSV-4单独和与亚MIC和亚协同浓度的LVX联合使用，显著减少了生物膜的形成。此外，RSV-3和RSV-4减少了软琼脂上的幽门螺杆菌游走运动。RSV、RSV-3和RSV-4对G. mellonella幼虫无毒，并对幽门螺杆菌感染显示出保护效果。总体而言，RSV-酚衍生物应被视为创新治疗方案的有趣候选者，以解决幽门螺杆菌的抗生素耐药性。

  DOI：

  10.3390/antibiotics9120891

文献信息

• Flow Chemistry Syntheses of Styrenes, Unsymmetrical Stilbenes and Branched Aldehydes
  作者：Samuel L. Bourne、Matthew O'Brien、Sivarajan Kasinathan、Peter Koos、Päivi Tolstoy、Dennis X. Hu、Roderick W. Bates、Benjamin Martin、Berthold Schenkel、Steven V. Ley

  DOI：10.1002/cctc.201200778

  日期：2013.1

  Two tandem flow chemistry processes have been developed. A single palladium‐catalysed Heck reaction with ethylene gas provides an efficient synthesis for functionalised styrenes. Through further elaboration the catalyst becomes multi‐functional and performs a second Heck reaction providing a single continuous process for the synthesis of unsymmetrical stilbenes. In addition, the continuous, rhodium‐catalysed

  已经开发了两种串联流化学方法。钯与乙烯气体的单催化Heck反应为官能化苯乙烯提供了有效的合成方法。通过进一步的精制，催化剂变为多功能，并进行第二次Heck反应，从而为不对称对苯二甲酸酯的合成提供了一个连续的过程。此外，苯乙烯衍生物与合成气的铑连续催化加氢甲酰化反应可提供具有良好选择性的支链醛。在线水洗和液-液分离相结合，使乙烯Heck反应可伸缩进入加氢甲酰化步骤，从而直接从芳基碘化物中直接合成支链醛。
• Formulation and process for modulating wound healing
  申请人：BioMendics, LLC

  公开号：US10426742B2

  公开（公告）日：2019-10-01

  Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I): wherein: L represents a linker selected from —C≡C—, (a tolan), —CH═CH— (a stilbene, preferably trans); or —CRa═CRb— a stilbene derivative; where Ra and Rb are independently H or phenyl optionally substituted with —(R3)p or —(R4)q; R1 to R4 are independent substituents at any available position of the phenyl rings, preferably at 3, 3′, 4, 4′, and/or 5, 5′; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be ≥1. Each R1 to R2 is independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein. The formulation may include a hydrogel formed by the compounds themselves or otherwise and may include salts and/or complexes.

  本发明公开了通过调节自噬促进伤口愈合的方法和化合物。用于调节自噬的制剂包括选自具有一般结构 (I) 的化合物的第一调节化合物 (FAM)： 其中L 代表选自-C≡C-（甲苯）、-CH═CH-（二苯乙烯，最好是反式）或-CRa═CRb-二苯乙烯衍生物的连接体；其中 Ra 和 Rb 独立地是 H 或任选被-(R3)p 或-(R4)q 取代的苯基； R1至R4是独立的取代基，位于苯基环的任何可用位置，优选位于3，3′、4，4′和/或5，5′；m、n、p和q分别独立地为0、1、2或3，代表环的取代基数目，但m或n中至少有一个必须≥1。每个 R1 至 R2 独立地选自本文所述的取代基，包括但不限于羟基、烷氧基、卤代、卤代甲基和苷。制剂还可包括本文所述的辅助自噬调节化合物（AAM）。制剂可包括由化合物本身或以其它方式形成的水凝胶，并可包括盐和/或复合物。
• Formulation and Process for Modulating Wound Healing
  申请人：BioMendics, LLC

  公开号：US20160296477A1

  公开（公告）日：2016-10-13

  Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I): wherein: L represents a linker selected from —C≡C—, (a tolan), —CH═CH— (a stilbene, preferably trans); or —CR a ═CR b — a stilbene derivative; where R a and R b are independently H or phenyl optionally substituted with —(R 3 ) p or —(R 4 ) q ; R 1 to R 4 are independent substituents at any available position of the phenyl rings, preferably at 3, 3′, 4, 4′, and/or 5, 5′; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be ≧1. Each R 1 to R 2 is independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein. The formulation may include a hydrogel formed by the compounds themselves or otherwise and may include salts and/or complexes.
• Kozachuk,D.N. et al., Journal of Organic Chemistry USSR (English Translation), 1971, vol. 7, p. 1976 - 1981
  作者：Kozachuk,D.N. et al.

  DOI：——

  日期：——
• Searching for New Tools to Counteract the Helicobacter pylori Resistance: The Positive Action of Resveratrol Derivatives
  作者：Paola Di Fermo、Silvia Di Lodovico、Rosa Amoroso、Barbara De Filippis、Simonetta D’Ercole、Emanuela Di Campli、Luigina Cellini、Mara Di Giulio

  DOI：10.3390/antibiotics9120891

  日期：——

  The drug-resistance phenomenon in Helicobacter pylori underlines the need of novel strategies to improve the eradication rate including alternative treatments combining antibiotic and non-antibiotic compounds with synergistic action. In this study, the antibacterial (MIC/MBC) and anti-virulence effects (biofilm reduction and swarming motility inhibition) of resveratrol-RSV and new synthetized RSV-phenol derivatives, with a higher bioavailability, alone and combined with levofloxacin-LVX were evaluated against resistant H. pylori clinical strains. The experiments were confirmed in vivo using the Galleria mellonella model. Among the studied RSV derivatives, RSV-3 and RSV-4 possessed higher antibacterial activity with respect to RSV (MICs from 6.25 to 200 µg/mL and from 3.12 to 200 µg/mL, respectively). RSV, RSV-3, and RSV-4 were able to synergize with LVX restoring its effect in two out of seven clinical resistant strains tested for the study. RSV, RSV-3, and RSV-4, alone and with LVX at sub-MIC and sub-synergistic concentrations, significantly reduced the biofilm formation. Moreover, RSV-3 and RSV-4 reduced the H. pylori swarming motility on soft agar. RSV, RSV-3, and RSV-4 were non-toxic for G. mellonella larvae and displayed a protective effect against H. pylori infection. Overall, RSV–phenol derivatives should be considered interesting candidates for innovative therapeutic schemes to tackle the H. pylori antibiotic resistance.

  幽门螺杆菌耐药现象强调了需要采用新策略来提高根除率，包括联合具有协同作用的抗生素和非抗生素化合物的替代治疗方法。本研究评估了白藜芦醇-RSV和新合成的具有更高生物利用度的RSV-酚衍生物，单独和与左氧氟沙星-LVX联合使用，对耐药的幽门螺杆菌临床菌株的抗菌效应（MIC/MBC）和抗毒力效应（生物膜减少和游走运动抑制）。使用Galleria mellonella模型在体内进行了确认实验。在研究的RSV衍生物中，RSV-3和RSV-4相对于RSV具有更高的抗菌活性（MIC分别为6.25至200 µg/mL和3.12至200 µg/mL）。RSV、RSV-3和RSV-4能够与LVX协同作用，恢复其在七种临床耐药菌株中的效果。RSV、RSV-3和RSV-4单独和与亚MIC和亚协同浓度的LVX联合使用，显著减少了生物膜的形成。此外，RSV-3和RSV-4减少了软琼脂上的幽门螺杆菌游走运动。RSV、RSV-3和RSV-4对G. mellonella幼虫无毒，并对幽门螺杆菌感染显示出保护效果。总体而言，RSV-酚衍生物应被视为创新治疗方案的有趣候选者，以解决幽门螺杆菌的抗生素耐药性。